Skip to main navigation
NextCure, Inc.
  • Home
  • About Us
    • Background
    • Founder
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • FIND-IO™ Technology
  • Pipeline
  • Product Development
  • Partnering
  • Investors
    • Overview
    • News
    • Publications
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Governance
    • SEC Filings
  • Contact

News Releases

News Releases

November 22, 2022   NextCure to Present at Upcoming Investor Conferences

November 15, 2022   NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates

November 7, 2022   NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

November 3, 2022   NextCure Provides Update and Reports Third Quarter 2022 Financial Results

November 3, 2022   NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting

October 27, 2022   NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

October 5, 2022   NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

October 4, 2022   NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

September 22, 2022   NextCure to Present at the Ladenburg Thalmann Healthcare Conference

August 4, 2022   NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 20

Tools

9000 Virginia Manor Road | Suite 200 | Beltsville, MD 20705 | USA | (240) 399-4900